Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Research & Development: 2009-2024

Historic Research & Development for Amicus Therapeutics (FOLD) over the last 16 years, with Dec 2024 value amounting to $109.4 million.

  • Amicus Therapeutics' Research & Development fell 10.49% to $23.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $142.3 million, marking a year-over-year increase of 24.60%. This contributed to the annual value of $109.4 million for FY2024, which is 28.23% down from last year.
  • According to the latest figures from FY2024, Amicus Therapeutics' Research & Development is $109.4 million, which was down 28.23% from $152.4 million recorded in FY2023.
  • Over the past 5 years, Amicus Therapeutics' Research & Development peaked at $308.4 million during FY2020, and registered a low of $109.4 million during FY2024.
  • Over the past 3 years, Amicus Therapeutics' median Research & Development value was $152.4 million (recorded in 2023), while the average stood at $179.5 million.
  • Its Research & Development has fluctuated over the past 5 years, first grew by 7.70% in 2020, then crashed by 44.92% in 2023.
  • Yearly analysis of 5 years shows Amicus Therapeutics' Research & Development stood at $308.4 million in 2020, then dropped by 11.80% to $272.0 million in 2021, then rose by 1.70% to $276.7 million in 2022, then plummeted by 44.92% to $152.4 million in 2023, then declined by 28.23% to $109.4 million in 2024.